Last updated: August 25, 2026
ChloraPrep Single Swabstick is a single-use topical antiseptic applicator containing chlorhexidine gluconate and isopropyl alcohol, typically formulated as 2% chlorhexidine gluconate in 70% isopropyl alcohol. BD owns and markets the ChloraPrep brand through its infection-prevention portfolio. The product competes in the hospital skin-antisepsis market, where demand is driven by surgical procedures, central-line insertion, catheter placement, and infection-control protocols.
No standalone revenue, operating profit, patent-expiration schedule, or product-level margin is publicly disclosed for ChloraPrep Single Swabstick. Its financial trajectory must therefore be assessed through BD’s broader Medical segment, hospital procedure volumes, contract pricing, product mix, manufacturing capacity, and competitive pressure from other chlorhexidine-alcohol products.
What is ChloraPrep Single Swabstick and how does it work?
ChloraPrep Single Swabstick is a sterile, single-use applicator for preparing intact skin before invasive procedures. Its active ingredients are chlorhexidine gluconate, which provides persistent antimicrobial activity, and isopropyl alcohol, which provides rapid broad-spectrum activity.
The product is used in settings including:
- Surgical-site preparation
- Central venous catheter insertion
- Peripheral and arterial catheter placement
- Interventional radiology
- Emergency medicine
- Intensive-care procedures
- Outpatient procedural centers
The single-swabstick format is intended for smaller preparation areas or procedures requiring a compact, ready-to-use applicator. The commercial value of the format comes from standardization and reduced preparation time rather than from a novel active pharmaceutical ingredient.
| Product characteristic |
ChloraPrep Single Swabstick |
| Product category |
Topical antiseptic |
| Active ingredients |
Chlorhexidine gluconate and isopropyl alcohol |
| Typical formulation |
2% chlorhexidine gluconate in 70% isopropyl alcohol |
| Dosage form |
Single-use applicator |
| Primary customers |
Hospitals, ambulatory surgery centers, clinics and emergency departments |
| Manufacturer |
Becton, Dickinson and Company |
| Main commercial value |
Procedure efficiency, infection-control standardization and ready-to-use delivery |
| Primary competitors |
3M SoluPrep, Cardinal Health antiseptic products, PDI and B. Braun products |
Product concentration, applicator volume, labeling and availability vary by jurisdiction and catalog number. The applicable package label controls the approved use and preparation technique.
What is the FDA regulatory status of ChloraPrep Single Swabstick?
ChloraPrep is an FDA-regulated topical antiseptic product marketed under an FDA-approved drug framework. FDA labeling identifies the product as a skin preparation containing chlorhexidine gluconate and isopropyl alcohol. The product is not a biologic and does not require a biosimilar pathway.
The U.S. regulatory profile has several commercial implications:
- The active ingredients have long clinical histories and are not dependent on exclusivity for market access.
- Product-specific manufacturing, packaging, sterility, applicator design and labeling remain important regulatory controls.
- The product must comply with drug current good manufacturing practice requirements.
- Alcohol content creates flammability and operating-room handling requirements.
- The labeling includes restrictions involving neonates, premature infants, mucosal surfaces, eyes, ears and damaged skin.
ChloraPrep products have historically been subject to FDA labeling updates and safety communications involving rare but serious hypersensitivity reactions associated with chlorhexidine-containing products. FDA has required stronger warnings for chlorhexidine products after reports of anaphylaxis and other serious allergic reactions.[1]
What patents protect ChloraPrep Single Swabstick?
ChloraPrep Single Swabstick is unlikely to have meaningful patent protection based on its active ingredients. Chlorhexidine gluconate and isopropyl alcohol are established compounds, and their basic antiseptic use is not a durable composition-of-matter moat.
The relevant intellectual-property categories are instead:
| IP category |
Relevance to ChloraPrep |
| Active-ingredient patents |
Limited or expired for the core ingredients |
| Formulation patents |
Potential protection for specific concentrations, stabilizers or compatibility profiles |
| Applicator patents |
Potential protection for swabstick construction, breakable ampules, fluid release and coating mechanics |
| Manufacturing know-how |
Important for sterility, fill volume, packaging integrity and scale-up |
| Trademark rights |
Important for the ChloraPrep brand |
| Regulatory data exclusivity |
Limited strategic importance for an established topical antiseptic |
| Trade secrets |
Potential value in production processes, quality controls and supply management |
The commercial barrier is therefore based more on regulatory compliance, hospital purchasing contracts, validated manufacturing, brand recognition and supply reliability than on a single blocking patent.
No current Orange Book patent estate for the Single Swabstick format should be assumed without product-specific FDA Orange Book and patent-listing verification. A competitor could potentially market a comparable chlorhexidine-alcohol applicator without infringing a composition patent, subject to FDA requirements and any enforceable device, formulation or packaging claims.
When does ChloraPrep lose exclusivity?
ChloraPrep does not have a conventional small-molecule exclusivity cliff comparable to a patented oral drug. Core ingredient exclusivity has long expired. Market access is controlled by a combination of regulatory approval, product-specific labeling, manufacturing capability, trademarks and institutional purchasing relationships.
This structure produces a gradual competitive erosion pattern:
| Exclusivity element |
Expected commercial effect |
| Active ingredients |
Little or no remaining exclusivity |
| Brand name |
Protects source identification but does not prevent competing products |
| Product approval |
Requires competitors to establish compliant products |
| Applicator design |
May create narrow protection if covered by enforceable claims |
| Hospital contracts |
Can delay switching even when alternatives are approved |
| Manufacturing validation |
Raises execution barriers |
| Clinical familiarity |
Supports brand retention and formulary preference |
Generic entry risk exists, but it is usually fragmented across manufacturers and package configurations rather than triggered by one date. The most material risk is contract conversion by group purchasing organizations, hospital systems and ambulatory surgery networks.
How large is the market for chlorhexidine-alcohol skin antiseptics?
The addressable market is linked to procedure volume rather than chronic prescription prevalence. Demand rises with surgical activity, catheter use, intensive-care admissions and outpatient procedures.
Key market drivers include:
- Hospital admissions and operating-room utilization
- Central-line and catheter placement volume
- Surgical-site infection prevention standards
- Preference for alcohol-based antiseptics
- Hospital quality programs
- Infection-prevention protocols
- Expansion of ambulatory surgery centers
- Conversion from multi-use preparation systems to single-use formats
Demand is less sensitive to consumer pharmaceutical spending than prescription medicines. Hospital budget pressure still affects pricing because antiseptics are frequently purchased through tenders, GPO contracts and system-wide formularies.
The market has two distinct segments:
Standard surgical preparation
Large-volume applicators are used for broad surgical fields. Competition is based on coverage area, drying time, packaging and unit cost.
Small-area procedural preparation
Single Swabstick products address smaller preparation fields. They can reduce waste when a full-size applicator is unnecessary. The format may command a higher price per milliliter, but hospitals may accept that premium when it reduces waste, improves workflow or supports standardized procedure kits.
How does ChloraPrep compare with competing skin-prep products?
ChloraPrep competes primarily against other chlorhexidine-alcohol products, not against systemic pharmaceuticals.
| Factor |
ChloraPrep Single Swabstick |
Povidone-iodine products |
Other CHG-alcohol products |
| Antimicrobial profile |
Rapid alcohol activity with persistent CHG activity |
Broad activity but different persistence profile |
Similar active-ingredient profile |
| Delivery |
Ready-to-use single-use applicator |
Swab, solution or applicator formats |
Varies by supplier |
| Main clinical use |
Procedure and catheter preparation |
Surgical and general antisepsis |
Procedure and institutional use |
| Differentiation |
Brand, applicator, labeling and supply reliability |
Familiarity, cost and broad availability |
Price, contract terms and packaging |
| Main limitation |
Alcohol flammability and chlorhexidine sensitivity |
Different clinical preferences and drying characteristics |
Less established brand recognition in some accounts |
3M’s SoluPrep line is a major branded competitor. Cardinal Health, PDI, B. Braun and private-label suppliers compete through product availability, pricing and bundled hospital supply agreements. Private-label competition is more consequential in standardized products with limited ingredient differentiation.
What is the financial trajectory for ChloraPrep Single Swabstick?
BD does not report ChloraPrep Single Swabstick as a separate revenue line. Public financial analysis must therefore use segment-level information and industry indicators.
BD reported consolidated revenue of approximately $20 billion in fiscal 2023, with revenues distributed across Medical, Life Sciences and Interventional segments.[2] ChloraPrep is associated with BD’s medical and infection-prevention activities, but BD’s public filings do not identify brand-level sales, volume, gross margin or regional performance.
The product’s likely financial trajectory has four stages:
1. Mature branded growth
The product benefits from established clinical use, recurring hospital demand and the low unit cost relative to a procedure. Revenue growth is generally tied to procedure volumes, account retention and price realization.
2. Mix expansion
Growth can come from expanded use of small-volume applicators, conversions from alternative preparation formats and inclusion in procedure-specific kits. Product mix can improve revenue even when unit volume grows slowly.
3. Contract-driven price pressure
Hospital systems and GPOs can reduce net pricing through competitive tenders. Volume commitments may preserve share while compressing gross margin. The product’s financial performance depends on maintaining a balance between premium brand pricing and contract participation.
4. Mature-market erosion
As comparable CHG-alcohol products become more available, market share can decline gradually. The risk is highest where procurement teams treat the products as interchangeable and clinical protocols do not require a specific brand.
| Financial variable |
Likely effect on ChloraPrep economics |
| Procedure volume |
Positive volume driver |
| Hospital staffing pressure |
May increase value of ready-to-use formats |
| GPO purchasing |
Supports scale but pressures price |
| Raw-material costs |
Affects margin, although active ingredients are established |
| Packaging costs |
Important because each unit is individually packaged |
| Sterility requirements |
Raises manufacturing and quality costs |
| Product recalls or shortages |
Can cause immediate share loss |
| Private-label entry |
Increases pricing pressure |
| Brand preference |
Supports retention and premium pricing |
| Ambulatory surgery growth |
Supports smaller-format demand |
The most defensible investment conclusion is that ChloraPrep is a mature, recurring-revenue medical product rather than a high-growth pharmaceutical asset. Its financial value lies in durable procedure-linked demand, account penetration and portfolio integration.
What manufacturing and supply-chain barriers affect ChloraPrep?
Manufacturing barriers are meaningful even without strong compound patents. The product combines flammable alcohol, an antiseptic active ingredient, sterile packaging and a specialized applicator. The manufacturer must control:
- Active-ingredient concentration
- Fill volume
- Applicator release performance
- Container-closure integrity
- Sterility assurance
- Alcohol evaporation
- Packaging compatibility
- Labeling and lot traceability
- Transport and storage conditions
- Production-site qualification
A shortage or recall can cause hospitals to switch quickly because procedure schedules cannot depend on one supplier. Once an alternative is validated, the original supplier may have difficulty recovering the account.
The single-use format also creates packaging exposure. Rising costs for plastics, films, foil, cartons and sterile manufacturing can pressure margins even when ingredient costs remain stable.
What litigation and settlement risks affect ChloraPrep?
There is no basis to identify a current product-specific patent litigation campaign or Paragraph IV settlement involving ChloraPrep Single Swabstick from the publicly available commercial profile. Paragraph IV litigation is generally associated with abbreviated new drug applications challenging listed patents for conventional pharmaceutical products. That framework is less central for an established topical antiseptic applicator without a clearly blocking Orange Book patent estate.
The principal legal risks are more likely to involve:
- Product-liability claims
- Alleged allergic reactions
- Fire or operating-room safety incidents
- Labeling adequacy
- Manufacturing defects
- Sterility failures
- False or unsupported infection-prevention claims
- Contract disputes
- Hospital procurement challenges
- Intellectual-property disputes over applicator construction or packaging
FDA labeling identifies chlorhexidine-related hypersensitivity as a significant safety issue.[1] This risk can create litigation exposure even when the product is used according to label.
What generic launch scenarios exist for ChloraPrep?
Three competitive-entry scenarios are commercially plausible.
Direct branded competitor
A large medical-supply company launches a comparable CHG-alcohol applicator and competes for GPO and hospital-system contracts. This is the most credible threat because the competitor can match regulatory, manufacturing and distribution requirements.
Private-label conversion
A hospital distributor or GPO introduces a private-label product with equivalent active ingredients and a lower acquisition price. Conversion risk is highest in accounts where the product is treated as a standardized commodity.
Format substitution
Hospitals replace small single swabsticks with alternative applicator volumes, bundled procedural kits or povidone-iodine products. This can reduce Single Swabstick volume without directly displacing the ChloraPrep brand across all product categories.
A rapid, nationwide generic erosion event is less likely than account-by-account share migration. The product does not depend on one patent expiry date, so the commercial outcome will be determined by contracting, supply performance and clinical acceptance.
How strong is the ChloraPrep patent and commercial estate?
The patent estate is likely moderate to weak for the active ingredients and stronger for selected delivery, packaging and process elements if valid claims remain enforceable. The broader commercial estate is more durable.
| Estate component |
Relative strength |
| Active-ingredient exclusivity |
Low |
| Brand recognition |
High |
| Hospital formulary presence |
Moderate to high |
| GPO access |
Important but contract-dependent |
| Applicator know-how |
Moderate |
| Manufacturing scale |
Moderate to high |
| Regulatory history |
Moderate |
| Switching costs |
Low to moderate |
| Clinical differentiation |
Moderate |
| Long-term pricing power |
Moderate to low |
The key strategic asset is the integrated product system: brand, regulatory file, manufacturing process, distribution network, hospital contracts and clinical familiarity. That combination can defend share even when the underlying chemistry is widely available.
What revenue exposure does ChloraPrep create for BD?
ChloraPrep is unlikely to represent a material percentage of BD’s consolidated revenue on a standalone basis. Its importance is strategic rather than transformational. The product can contribute recurring revenue, account access and cross-selling opportunities within BD’s broader hospital portfolio.
Revenue exposure is concentrated in:
- U.S. hospital procedures
- Infection-prevention budgets
- GPO contracts
- Central-line and catheter protocols
- Surgical and ambulatory-care utilization
- Supply continuity
A product-specific disruption would likely be immaterial to BD’s total company revenue but could affect infection-prevention category performance, customer relationships and contract renewals.
Key Takeaways
- ChloraPrep Single Swabstick is a single-use chlorhexidine-alcohol skin antiseptic marketed by BD.
- Its commercial value comes from ready-to-use delivery, established clinical use, regulatory compliance and hospital contracts.
- Core ingredient patent protection is not the primary barrier to competition.
- No public standalone revenue or margin data is available for the product.
- Financial performance is tied to procedure volume, GPO pricing, hospital-system retention and product mix.
- The main competitors include 3M SoluPrep, Cardinal Health, PDI, B. Braun and private-label suppliers.
- Generic risk is gradual and account-based rather than centered on a single patent-expiration date.
- The main legal exposures are product liability, allergic reactions, labeling, sterility and manufacturing quality.
- BD’s broader financial results provide the relevant public framework, but they do not isolate ChloraPrep performance.
FAQs
Is ChloraPrep Single Swabstick a prescription drug?
ChloraPrep is an FDA-regulated topical antiseptic product used primarily in healthcare settings. Its distribution and use depend on the specific product presentation, labeling and jurisdiction.
Can hospitals substitute a generic CHG-alcohol swabstick for ChloraPrep?
Hospitals can evaluate and substitute comparable products subject to formulary approval, procurement requirements, clinical protocols, product labeling and supply validation.
Does ChloraPrep Single Swabstick contain iodine?
No. ChloraPrep uses chlorhexidine gluconate and isopropyl alcohol. Povidone-iodine products are a separate antiseptic category.
Is ChloraPrep safe for infants?
Chlorhexidine products carry age-related and anatomical-use warnings. Use in neonates and young infants must follow the applicable FDA labeling, institutional protocol and clinical judgment.
Does BD disclose ChloraPrep sales separately?
No. BD reports financial results by operating segment and does not publicly disclose revenue, volume or profit for ChloraPrep Single Swabstick as a separate product.
References
- U.S. Food and Drug Administration. (2017). FDA warns about rare but serious allergic reactions with chlorhexidine gluconate. https://www.fda.gov
- Becton, Dickinson and Company. (2023). 2023 annual report. https://investors.bd.com
- U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drug products. https://www.accessdata.fda.gov/scripts/cder/daf/
- Becton, Dickinson and Company. (2024). ChloraPrep product information and labeling. https://www.bd.com
